IBEX heads into its May 7 earnings with an unusually call-heavy options market — a striking contrast to the cautious hedging seen in most pre-print setups.
The clearest signal into this earnings is from the options desk. The put/call ratio is running at just 0.17, more than two standard deviations above its 20-day mean of 0.14 — and in this case, the skew is overwhelmingly toward calls, not puts. That makes options positioning here more bullish than it has been for most of the past year. Borrow conditions reinforce the picture: availability is extremely loose, with ORTEX showing availability near the ceiling of the lending pool, and the cost to borrow is only 1.35% — cheap even after doubling over the past week. Short sellers aren't pressing their bets into the print.
Short interest itself is a secondary story. At 1.25% of the free float, bears haven't made IBEX a high-conviction target. Shorts have actually retreated sharply — down 24% over the past month — after briefly peaking above 220,000 shares in early April. That unwind has coincided with the stock clawing back roughly 1.5% on the month, closing at $28.11. Peers in the data-processing space have had a rougher week: TNET fell over 4.5% and shed more than 5% on the week, making IBEX's relative stability look notable by comparison.
The analyst picture is split. The mean price target of $37.50 implies roughly 33% upside from current levels, yet both active coverage firms hold neutral-to-cautious stances — RBC Capital at Sector Perform and Baird at Neutral as of last year. Coverage is thin, and the most recent formal analyst actions are stale relative to today's price level, so that target should be treated with caution. The bull case centers on an 18% revenue acceleration, a growing shift toward digital and omni-channel delivery now at 82% of total revenue, and the ramp of generative AI implementations. Bears point to shrinking contributions from telecom (down to 10.9% of revenue) and technology verticals (7.4%), plus exposure to operating conditions in politically sensitive geographies.
The insider picture carries one note worth flagging. CEO Robert Dechant sold 30,000 shares in a structured pattern through late February — five tranches of 6,000 shares each — at prices between $28.46 and $29.98. The stock has since drifted back to those same levels. The CEO simultaneously received a stock award of more than 124,000 shares in early February, so the net insider position isn't clearly bearish, but the open-market selling was concentrated at prices close to where the stock trades today. The last earnings print, in February, produced a 4% drop on the day and a 12% decline over the following five sessions — making this print a test of whether that pattern repeats or whether the bullish options skew reflects genuine confidence in a better delivery.
See the live data behind this article on ORTEX.
Open IBEX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
